Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.58 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 2/20 | 0.42 |
| ▸ | MMP9 | P14780 | 2/20 | 0.42 |
| ▸ | MMP8 | P22894 | 2/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.40 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19600024 | 0.99 | L3MBTL1 (0.57) | L3MBTL1PPARATDP1PPARGMMP3 | |
| SCHEMBL18282351 | 0.99 | L3MBTL1 (0.57) | L3MBTL1PPARATDP1PPARGMMP3 | |
| SCHEMBL17940942 | 0.99 | L3MBTL1 (0.57) | L3MBTL1PPARATDP1PPARGMMP3 | |
| SCHEMBL17941127 | 0.97 | L3MBTL1 (0.59) | L3MBTL1PPARATDP1PPARGMMP3 | |
| SCHEMBL17941107 | 0.97 | L3MBTL1 (0.62) | L3MBTL1PPARATDP1PPARGMMP3 | |
| SCHEMBL16346501 | 0.96 | L3MBTL1 (0.54) | L3MBTL1PPARATDP1PPARGMMP3 | |
| SCHEMBL17940957 | 0.96 | L3MBTL1 (0.54) | L3MBTL1PPARATDP1PPARGMMP3 | |
| SCHEMBL18530395 | 0.96 | L3MBTL1 (0.54) | L3MBTL1PPARATDP1PPARGMMP3 | |
| SCHEMBL26116555 | 0.96 | L3MBTL1 (0.54) | L3MBTL1PPARATDP1PPARGMMP3 | |
| SCHEMBL4140935 | 0.96 | L3MBTL1 (0.56) | L3MBTL1PPARATDP1PPARGMMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361248-A1 | PROTAC COMPOUND WITH CYCLOPHILIN A DEGRADATION ACTIVITY, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shenzhen Bay Laboratory (CN) | 2025-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361248-A1 | PROTAC COMPOUND WITH CYCLOPHILIN A DEGRADATION ACTIVITY, PREPARATION METHOD THEREFOR, AND USE THEREOF | PPIA, PPIG, PPIF | L3MBTL1 4638/4885PPARA 591/4885TDP1 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.